Tebipenem's approval in 2026 under SPA could bring Spero $400M+ in milestones & royalties. Read more on why SPRO is a Buy, given acquisition interest and other upside potential.

By Kelly Cloonan Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint.

Esther Rajavelu, Chief Executive Officer, Spero, said: "Achieving the primary endpoint in the PIVOT-PO trial marks a significant milestone for tebipenem HBr. If approved, we believe tebipenem HBr is ...

CAMBRIDGE, Mass. - Spero Therapeutics, Inc. (NASDAQ:SPRO), a biopharmaceutical company specializing in novel treatments for rare diseases and multi-drug resistant infections, announced the ...

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | Having stripped back its workforce, antibiotics biotech Spero ...

Good afternoon and welcome to the Spero Therapeutics fourth-quarter and full-year 2024 earnings conference call. At this time, all participants are on listen-only mode. Following the company's ...

Analyzing Analyst Ratings: A Detailed Breakdown The standing of Spero Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions.

--Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial ...

Spero saw potential dose-limiting safety issues in people who received 1,000 mg of SPR720 orally once daily. The safety issues included three cases of reversible grade 3 hepatotoxicity. The mix of ...

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets ...

Global architecture firm Streetsense approached the design of Bar Spero, a Spanish seafood restaurant in Washington, D.C., by looking toward its chef, Johnny Spero.